Daré Bioscience Announces the Upcoming Launch of Flora Sync LF5™ Vaginal Probiotic Capsules

About this update from Dare Bioscience, Inc.

First Product Revenue Expected This Month, Opening New Commercial Chapter for Women's Health Innovator Limited-Time Launch Offer: 30% Off + Free Shipping SAN DIEGO, June 04, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced the upcoming commercial launch of Flora Sync LF5™, a vaginal probiotic capsule formulated specifically to restore microbiome balance and support lasting vaginal comfort. The launch represents a milestone for Daré, as the company expects to generate its first direct consumer product revenue in June 2026, marking the company's transition from a pure development-stage biotech to a women's health company with a revenue-generating product. Flora Sync LF5™ will be marketed under the brand family DARE to RESTORE™ and manufactured by Probiotical S.p.A., a global leader in probiotic development and manufacturing. "Flora Sync LF5 was developed specifically for vaginal health, not gut health," said Sabrina Martucci Johnson, President and Chief Executive Officer of Daré Bioscience. "By delivering a vagina-specific probiotic strain directly to the vaginal environment, Flora Sync LF5 represents a targeted approach to supporting vaginal wellness. This upcoming launch marks an important milestone for Daré as it represents the company’s first consumer health product launch. We continue to work to bring women other innovative, science-backed products they can access directly, without a prescription. We look forward to making Flora Sync LF5 available to women across the country and sharing our first commercial results with investors and our community." ABOUT FLORA SYNC LF5™ (DARE TO RESTORE™) Flora Sync LF5 is a targeted, non-hormonal probiotic vaginal capsule formulated with Limosilactobacillus fermentum LF5, a clinically studied probiotic strain originally isolated from the vaginal microbiome of healthy women with no reported history of yeast infections and backed by over 30 years of research. Unlike most probiotics marketed for vaginal health, which rely on gut strains taken orally, Flora Sync LF5 delivers a vagina-specific probiotic strain directly to the vaginal environment, where imbalance occurs. This targeted approach is designed to support a healthy vaginal microbiome, natura...

View stock analysis, news, and events for Dare Bioscience, Inc.